31 32 2 Key Points: 33 Key Point 1: Intra-BM transfusion of MSCs restores the BM microenvironment, improves 34 thrombopoiesis, and suppresses MDS/MPN initiated by Nras mutation. 35 Key Point 2: Donor MSCs reprogram macrophages to restore the BM microenvironment, improve 36 thrombopoiesis, and suppress leukemia. 37 3 Abstract 38 Bone marrow (BM) mesenchymal stem cells (MSCs) are critical components of the BM 39 microenvironment and play an essential role in supporting hematopoiesis. Dysfunction of MSCs 40 is associated with the impaired BM microenvironment that promotes leukemia development. 41 However, whether and how restoration of the impaired BM microenvironment can inhibit 42 leukemia development remain unknown. Using an established leukemia model and the RNA-seq 43 analysis, we discovered functional degeneration of MSCs during leukemia progression. 44
Introduction 55 BM MSCs are key components of the BM stromal microenvironment, regulating homeostasis of 56 the stromal niche and hematopoiesis 1 . Accumulating evidence uncovers that dysfunction of MSCs 57 is associated with leukemia progression. Leukemic MSCs in a mouse T-ALL model suppressed 58 normal hematopoiesis 2 . Deletion of Dicer1 gene in MSCs leads to impaired osteogenic 59 differentiation, thrombopenia, and secondary tumorigenesis 3 . In myeloproliferative neoplasms, the 60 leukemic cells reprogram MSCs to support proliferation of leukemic stem cells 4 . Ablation of MSC-61 derived osteoblasts impairs the homeostasis of hematopoietic stem cells (HSC) and accelerates 62 leukemogenesis in chronic myeloid leukemia 5 . In a myelodysplastic/myeloproliferative neoplasms 63 (MDS/MPN) model, Ptpn11 mutation in MSCs hyperactivates HSC by secreting CCL3, 64 systemically resulting in myeloid-biased proliferation and promoting leukemia progression 6 . 65 Chromosomal abnormalities in MSCs occur in over 16% MDS/acute myeloid leukemia (AML) 66 patients, which leads to a shorter survival 7 . MSCs of every MDS patient show features of stemness 67 loss, aging, and osteogenic differentiation defect, which results in insufficient hematopoiesis 8 . In 68 a patient-derived xenograft (PDX) model, only co-transplantation of tumor cells and the same 69 patient-derived MSCs successfully recapitulates the MDS phenotype, indicating that besides the 70 loss of function of supporting hematopoiesis, MSCs in MDS patients may acquire a function of 71 preferentially promoting tumorigenesis 9 . Despite these findings, the causal relationship between 72 tumor cells and the BM microenvironment during leukemia development and progression remains 73 elusive. 74 MSC therapy has been widely used in treating immune-related graft-vs-host disease (GVHD) and 75 inflammation-related diseases 10, 11 . Over the decades, a lot of evidence demonstrates that MSCs 76 regulate innate and adaptive immune responses largely by secreting distinct sets of cytokines, 77 5 growth factors, and chemokines depending on different disease contexts [12] [13] [14] [15] [16] . Given the short 78 lifespan of donor MSCs after transfusion 17 , the underlying molecular and cellular mechanisms by 79 which these cells produce therapeutic effects remain elusive. It is also completely unknown 80 whether donor MSCs can restore the impaired BM microenvironment and consequently suppress 81 disease progression in leukemia setting. 82
Macrophages are pivotal for maintenance of the tissue microenvironment, tissue repair, and even 83 the tumor microenvironment [18] [19] [20] [21] [22] . BM resident macrophages maintain the homeostasis of HSCs 84 and loss of these macrophages leads to mobilization of HSCs into peripheral blood (PB) 23 . The 85 functions of macrophages are plastic and can be reshaped by distinct sets of soluble factors. When 86 performing tissue repair, macrophages highly express arginase 1 (Arg1) 24 , an enzyme that converts 87 L-arginine to urea and L-ornithine. After co-culture with MSCs, macrophages can be polarized 88 from pro-inflammation (M1) to anti-inflammation (M2) type, up-regulating IL-10 and CD206 and 89 down-regulating IL-6 and IL-1β 25 . Upon stimulated by LPS or TNF-α, MSCs can cross-talk with 90 lung macrophages and reprogram these macrophages to secrete IL-10 to alleviate sepsis 26 . Despite 91 these knowledge, whether healthy MSCs can reprogram macrophages from leukemia-bearing host 92 to repair the damaged BM microenvironment is not known. 93
Using the established mouse model mimicking chronic MPN/MDS diseases 27-29 , we discovered 94 that the deteriorating BM microenvironment was associated with disease progression. Intra-BM 95 instead of systemic transfusion of healthy MSCs restored the local BM microenvironment, 96 improved thrombopoiesis, reduced tumor burden, and prolonged survival of leukemia-bearing 97 mice. Mechanistically, we found that MSCs suppress leukemia development through resident 98 macrophages and autocrine effect of IL-6. Our study demonstrates that intra-BM transfusion of 99 7 RNA-Seq and data analysis. For MSC library preparation, MSCs were sorted from wild type or 122 leukemia-bearing mice, and recovered MSCs were sorted from leukemia-bearing mice 8 weeks 123 post treatment with GFP + donor MSCs. MSCs were sorted from two mice of each group. 1000 124 target cells per sample were sorted into 500 µl DPBS-BSA buffer (0.5%BSA) using 1.5ml EP tube 125 and transferred into 250 µl tube to spin down with 500 g. The cDNA of sorted 1000-cell aliquots 126 were generated and amplified as described previously 30 . The qualities of the amplified cDNA were 127 examined by Q-PCR analysis of housekeeping genes (B2m, Actb, Gapdh, Ecf1a1). Samples passed 128 quality control were used for sequencing library preparation by illumina Nextera XT DNA Sample 129
Preparation Kit (FC-131-1096) . 130
For macrophages (in vivo) library preparation, macrophages were sorted from BM of leukemia-131 bearing mice before or after MSC treatment (12 hours post MSC treatment). Macrophages were 132 also sorted after 12 hours of co-culture with MSCs. 1 × 10^5 target cells per sample were sorted 133 and total RNA was extracted using the RNeasy micro kit with on-column DNase treatment 134 (Qiagen, 74004) according to manufacture's protocol. cDNA library was constructed using 135 VAHTSTM mRNA-seq V3 Library Prep Kit for Illumina (Vazyme, NR611) according to 136 manufacture's protocol. The qualities of the cDNA were examined by qPCR analysis of 137 housekeeping genes (B2m, Actb, Gapdh, Ecf1a1) . Samples that passed quality control were used 138 for sequencing. 139
For data analysis, all libraries were sequenced by illumina sequencers NextSeq 500. The fastq files 140 of sequencing raw data samples were generated using illumina bcl2fastq software (version: 141 2.16.0.10) and were uploaded to Gene Expression Omnibus public database (GSE 125029). Raw 142 reads were aligned to mouse genome (mm10) by HISAT2 31 (version: 2.1.0) as reported. And raw 143 counts were calculated by featureCounts of subread 32 (version 1.6.0). Differential gene expression 144 8 analysis was performed by DESeq2 33 (R package version: 1.18.1). Unsupervised clustering 145 analysis was performed using facotextra (R package, version：1.0.5). Heatmaps were plotted 146 using gplots (R package, version 3.01). GSEA was performed as described 34 , and gene-ontology 147 (GO)-enrichment analysis were performed by clusterProfiler 35 (R package, version: 3.6.0). MSC 148 stemness related genes and MSC osteogenesis related genes for heatmaps were from references as 149 follows: MSC stemness-related genes [36] [37] [38] were injected with DPBS following the same treatment procedure as MSCs. Analysis of platelets 163 and CD11b + cells in PB was performed monthly. 164 GFP-MSCs and BM macrophage co-culture assay. Short-term co-culture assay was performed, 165 with each well containing: 1 × 10^5 GFP-MSCs (passage 2; healthy MSCs were isolated from 166 GFP mice, Il6 -/-MSCs were isolated from Il6 -/mice) and 2 × 10^6 CD11b + leukemic cells sorted 167 9 from leukemia-bearing mice in 2 mL culture medium of α-MEM, 10% FBS and 50 ng/ml SCF. 168
MSCs and CD11b + leukemic cells were incubated either by direct-contact culture or transwell 169 culture for 12 hours at 37 o C under 5% CO 2 in a humidified incubator. MSC-reprogrammed 170 macrophages from leukemia-bearing mice (CD11b + F4/80 + ) were sorted for detecting the gene 171 expression by Q-PCR. 172
Treatment for leukemia-bearing mice with MSC-reprogrammed macrophages. 1 × 10^5 173
MSCs were seeded into each well of six-well plates. CD11b + leukemic cells were enriched from 174 BM of leukemia-bearing mice with severe tumor burden (CD11b + % in PB > 60%). Then 2 × 10^6 175 CD11b + leukemic cells were directly co-cultured with MSCs. After 12 hours, macrophages were 176 sorted for transfusion. Leukemia-bearing mice with severe tumor burden were treated by intra-BM 177 transfusion of PBS or MSC-reprogrammed macrophages from leukemia-bearing mice (E-Mac). A 178 dose of 1 million macrophages/mouse in 20 µl PBS were delivered into the tibia cavity using 29-179 gauge needle. Every tibia was treated once per two weeks by switching the injection site every 180 other dose. Analysis of platelets and CD11b + cells in PB was performed monthly. 181
Statistical analysis. The data were represented as mean ± SD. Two-tailed independent Student's 182 t-tests were performed for comparison of two groups of data (SPSS v.23, IBM Corp., Armonk, 183 NY, USA) . For the analysis of three groups or more, one-way ANOVA was used (SPSS v.23, IBM 184 Corp., Armonk, NY, USA), and further significance analysis among groups was analyzed by Post 185
Hoc Test (equal variances, Turkey-HSD; unequal variances, Games-Howell). Kaplan-Meier 186 method was used to calculate survival curves of leukemia, and Log-rank (Mantel-Cox) test was 187 performed to compare differential significance in survival rates. P values of less than 0.05 were 188 considered statistically significant (*p < 0.05, **p < 0.01, ***p < 0.001). 189
Results 190 10
Deterioration of BM MSCs accompanies the development of Nras-mutant-induced leukemia 191
Mice carrying an endogenous mutant Nras allele develop myelodysplastic/myeloproliferative 192 neoplasms (MDS/MPN)-like leukemia with a long latency [27] [28] [29] 43 . Here we found the primary BM 193 leukemic cells failed to accelerate the disease in the secondary recipient mice, implying a role of 194 the BM microenvironment in disease etiology ( Figure S1 ). We hypothesized that the BM 195 microenvironment is impaired by Nras-mutant leukemic cells, which in return impedes normal 196 hematopoiesis and accelerates leukemia progression. Indeed, we observed quantitative decreases 197 and functional degeneration of MSCs (Ter119 -CD45 -CD31 -Sca1 + CD51 + CD146 + ) during disease 198 development and progression ( Figure 1A -C, and Figure S2 ). To further characterize the residual 199
MSCs in mice with leukemia, we performed RNA-Seq analysis of the residual MSCs from 200 leukemia-bearing mice at an early disease phase (CD11b + % in PB: 35%-45%). Consistent with 201 the quantitative and functional reduction, the expression of the transcription factor Gnl3 36 , an 202 indicator of MSC self-renewal, was significantly down-regulated in MSCs from leukemia-bearing 203 mice relative to wild-type mice ( Figure 1D ). The expression of Nt5e (CD73), Thy1 (CD90), Vcam1 204 (CD106), Cd81, Sdc4, Itgb1 and Anpep 36-38 , encoding surface markers on three-lineage-potent 205
MSCs but not on uni-lineage-primed MSCs, was markedly reduced in MSCs from leukemia-206 bearing mice (padj < 0.05, fold change > 1.6) ( Figure 1D ). Furthermore, the expression of Bgn, 207 Bmp4, Col1a1, Csf1, Dcn, Dkk2, Mmp13, Ogn, Wisp1, and Wisp2 36, 39 , pivotal for osteogenic 208 differentiation, was markedly suppressed in the residual MSCs (padj < 0.05, fold change > 2) 209 ( Figure 1E ). In vitro differentiation assay confirmed that osteogenic and adipogenic differentiation 210 potential in leukemic MSCs were impeded ( Figure S3 ). MSCs fulfill their tissue-specific and 211 condition-responsive regulatory functions through secreting distinct types of soluble factors 44 . 212 Under leukemia condition, the residual MSCs indeed secreted much less soluble factors, including 213 11 Il6, Il11, Ccl2, Ccl7, Cxcl12, Cxcl13 and Cxcl14 (padj < 0.05, fold change > 2), compared to MSCs 214 from normal wild-type mice ( Figure 1F ). These molecules are pivotal for tissue repairing 45-50 . 215 Indirect immunofluorescence assay and intracellular flow cytometry staining confirmed that the 216 levels of IL-6 ( Figure 1G Figure S4 ). Collectively, these results show that the MSCs dramatically 222 deteriorate during the disease development and progression of Nras-mutation-caused leukemia. 223
Intra-BM transfusion of healthy MSCs improves thrombopoiesis, reduces tumor burden and 224 improves survival of the leukemia-bearing mice 225
We hypothesized that restoration of the impaired BM microenvironment in leukemia-bearing mice 226 might suppress/delay the disease progression. To test this hypothesis, we attempted healthy MSC 227 treatment using GFP-tagged MSCs isolated from the tibias and femurs of healthy mice as 228 previously reported 53 . The isolated primary MSCs were expanded shortly in vitro to passage two 229 (P2) and cryopreserved. For MSC treatment, the cryopreserved P2 MSCs were recovered and 230 cultured for five days, phenotypically identified (CD45 -Ter119 -CD31 -231 CD51 + CD105 + LepR + PDGFRα + PDGFRβ + Sca1 + ) ( Figure S5 ), and suspended in DPBS (2.5 × 232 10^7/ml) for transfusion. Initially, we adopted a direct delivery procedure by injecting donor 233
MSCs every two weeks either via tail vein (dose: 0.5 × 10^6/mouse) ( Figure S6A ) or retro-orbital 234 (dose: 0.5 × 10^6/mouse) transfusion ( Figure S6B ) into the leukemia-bearing mice at a late disease 235 phase (CD11b + cells > 60% in PB). However, these delivery approaches failed to produce 236 12 therapeutic effects. In vitro cultured MSCs lose their natural homing feature 54 , the retro-orbital and 237 intravenous injection of cultured MSCs failed to home to bone marrow ( Figure S6C-D) . Thus, we 238 attempted intra-BM transfusion to overcome the homing defect caused by in vitro culture. A 239 sequential doses of MSCs (2.5 × 10^7 MSCs/kg per dose in 20 µL DPBS) were injected into the 240 tibia cavities of leukemia-bearing mice with two-week intervals for up to 16 weeks (Figure 2A) . 241
Strikingly, the tumor burden continuously decreased during MSC treatment ( Figure 2B and 242 Supplementary Figure S7 ). Consequently, the survival of treated leukemia-bearing mice was 243 significantly prolonged (Untreated: 51.5 days, MSC-treated: >115 days, p < 0.001) ( Figure 2C ). 244
Therefore, intra-BM transfusion of healthy donor MSCs improves the survival of leukemia-245 bearing mice. 246
MSC-treatment systemically re-balances myelopoiesis and activates megakaryopoiesis 247
We next investigated the underlying mechanisms associated with the systemically decreased tumor 248 burden. We found that the hematopoiesis in the MSC-treated leukemia-bearing mice was re-249 balanced, demonstrated by significant decreases of white blood cells (Untreated vs. MSC-treated: 250 23.04 vs 8.876, p = 0.009), and significant elevation of platelets (Untreated vs. MSC-treated: 2.64 251 vs. 6.01, p = 0.004) ( Figure 2D ) in PB. On the contrary, the PBS-treated leukemia-bearing mice 252 exhibited neither improved hematopoiesis ( Figure S8 ) nor prolonged survival. High GM-CSF 253 levels in serum are associated with the tumor burdens of CMML in patients 55 and mouse models 27 . 254
We analyzed the GM-CSF levels in serum of leukemia-bearing mice with or without MSC-255 treatment. As expected, the GM-CSF levels in MSC-treated leukemia-bearing mice were 256 significantly decreased (> 7 folds) (p < 0.001) ( Figure 2E ), which was associated with the reduction 257 of GM-CSF secreting tumor cells ( Figure S9 ). IL-6 promotes thrombopoiesis by increasing 258 systemic TPO levels 56 . Consistently, the MSC-treated leukemia-bearing mice exhibited elevated 259 13 IL-6 (> 25 folds) and TPO (> 2 folds) levels ( Figure 2F ) in PB serum. Collectively, these results 260 indicate that intra-BM transfusion of healthy donor MSCs systemically improves hematopoiesis 261 and prolongs the survival of leukemia-bearing mice. 262
To further investigate the systemic effects of the local MSC-treatment on hematopoiesis in 263 leukemia-bearing mice, we analyzed the ratios of myeloid progenitor subpopulations in MSC-264 treated leukemia-bearing mice. Consistent with the elevated platelet levels and reduced myeloid 265 cells in PB, the MSC-treated leukemia-bearing mice showed increased proportions of 266 megakaryocyte-erythroid progenitors (MEP) (> 1.6 folds) (p < 0.001) and decreased ratios of 267 granulocyte-macrophage progenitors (GMP) (> 1.5 folds) (p < 0.001) in both injected and non-268 injected sites than those sites in PBS-treated leukemia-bearing mice ( Figure 3A -B, Figure S10A) . 269
In addition, we observed increased (> 1.3 folds) ratios of mature megakaryocytes (≥ 8N) in both 270 injected and non-injected sites in MSC-treated leukemia-bearing mice ( Figure 3C -D, Figure S10B ) 271 in comparison with PBS-treated leukemia-bearing control mice (p < 0.001). Thus, these data 272 demonstrate that MSC-treatment systemically re-balances myelopoiesis and activates 273 megakaryopoiesis in leukemia-bearing mice. 274
Recovered host MSCs are functional as healthy counterparts 275
Consistent with an early report 57 , our data showed that MSCs indeed support normal 276 hematopoiesis. Interestingly, MSCs also promoted the growth of leukemic cells in vitro, which 277 suggests that donor MSCs indirectly inhibit the tumor development in vivo. To investigate whether 278 the improved hematopoiesis is associated with restoration of the BM microenvironment, we 279 analyzed the MSC-treated tibias eight weeks after MSC treatment. Interestingly, host MSCs (GFP 280 negative) were partially recovered ( Figure 4A-B) , but restricted to the locally treated tibias (Figure 281 S11). Functionally, the recovered host MSCs formed markedly more CFU-F colonies than the 282 14 residual MSCs from untreated leukemia-bearing mice (> 3.8 folds) (p < 0.001) ( Figure 4C and 283 Figure S12 ). To characterize the recovered MSCs at the transcriptome level, we sorted the 284 recovered MSCs for RNA-Seq analysis. Unsupervised hierarchical clustering analysis showed that 285 the recovered MSCs clustered closer to healthy MSCs ( Figure 4D) . Further, the expression of 286 cytokines and chemokines, including Il6, Ccl2, Ccl7, Ccl19, Cxcl12, Cxcl13, and Cxcl14, was 287 restored in the recovered MSCs compared to that in MSCs from untreated leukemia-bearing 288 control mice (padj < 0.05, fold change > 2) (p < 0.05) ( Figure 4E ). Consistently, indirect 289 immunofluorescence assay and intracellular flow cytometry staining confirmed that the levels of 290 IL-6, CCL2, and CXCL12 proteins in recovered MSCs (from the injected sites) were significantly 291 improved to comparable levels as in healthy MSCs (p < 0.001) ( Figure 4F -I and S13). Therefore, 292 donor MSC-treatment results in local functional restoration of host MSCs. 293
The donor MSCs reprogram macrophages to execute tissue-repair function 294
We further investigated the cellular mechanism underlying the restored BM microenvironment 295 mediated by donor MSCs under leukemia condition. BM macrophages play a pivotal role in 296 maintaining the BM niche 18 . To study whether donor MSCs reprogram BM macrophages, we 297 performed co-culture assay of healthy MSCs with BM macrophages (L-Mac) sorted from the 298 leukemia-bearing mice in vitro for twelve hours and re-sorted the macrophages (E-Mac) for RNA-299 Seq analysis. GSEA illustrated that angiogenesis-related genes, including Vegfa, Hif1a, Serpine1, 300
Eng and Thbs1 40 ( Figure S14A ), were enriched among the differentially expressed genes in E-Mac 301 ( Figure 5A ). Genes associated with cell migration, including Sirpa and Ccl5 58,59 , were also 302 enriched in E-Mac ( Figure 5B and S14B). Further, gene-ontology analysis demonstrated features 303 of positive regulation of cell migration and angiogenesis in E-Mac ( Figure 5C ). Elevated 304 expression of genes encoding soluble factors, including Tnf, Il1a, Ccr7, Ccl3, and Ccl5, was also 305 15 observed in E-Mac ( Figure 5D ). Indirect immunofluorescence assay confirmed that E-Mac had 306 significantly higher levels of TNF-α, CCR7, and IL-1α proteins than L-Mac (p < 0.001) ( Figure  307 5E and S15A). Furthermore, intracellular flow cytometry staining also showed that the levels of 308 TNF-α and CCR7 proteins in L-Mac were significantly lower than E-Mac (p < 0.001) ( Figure  309 S15B-D). To characterize which subset of macrophages are involved in re-educating the bone 310 marrow microenvironment, we analyzed the classical M1 and M2 macrophage subtypes both in 311 vitro and in vivo. However, the results showed that MSC treatment caused no typical transition of 312 M1 and M2 ( Figure S16 ), which indicates a functional alteration of leukemic macrophages 313 independent of M1 to M2 transition. RNA-Seq analysis showed that the expression of arginase 1 314 (Arg1), an indicator of tissue repair function 24 , was dramatically up-regulated over thousand folds 315 in E-Mac ( Figure 5F ) after direct co-culture with MSCs in vitro. However, the Arg1 expression in 316 macrophages after transwell co-culture was barely elevated ( Figure 5F) , indicating that direct cell-317 cell interaction instead of MSC-secreted soluble factors is essential for the functional 318 reprogramming. Consistent with the observation in vitro, the expression of Arg1 was also 319 significantly increased in BM macrophages directly isolated from MSC-treated leukemia-bearing 320 mice ( Figure 5G ). Furthermore, intracellular flow cytometry staining confirmed that the ratios of 321 Arg1 high macrophage subpopulation significantly increased in E-Mac at the MSC-treated sites (p 322 < 0.01) ( Figure 5H-I) . Collectively, these results indicate that the donor MSCs reprogram BM 323 macrophages from leukemia-bearing mice to execute tissue-repair function. 324
The E-Mac treatment largely recapitulates the therapeutic effects of MSC treatment 325
Given the short lifespan of donor MSCs in vivo 17 , we speculated that MSCs mediate the restoration 326 of the BM microenvironment of leukemia-bearing mice by reprogramming macrophages. We 327 isolated macrophages from leukemia-bearing mice and co-cultured them with healthy MSCs for 328 16 12h, and then transplanted these E-Mac back into leukemia-bearing mice by intra-BM injection 329 ( Figure 6A ). We indeed found that the thrombopoiesis was significantly improved (> 6 folds) after 330 E-Mac treatment (p < 0.001) ( Figure 6B-C) . Host MSCs were also significantly increased (> 3 331 folds) in E-Mac-treated leukemia-bearing mice (p < 0.001) ( Figure 6D-E) . Consistent with the 332 MSC treatment, we also observed increased ratios of mature megakaryocytes (p < 0.001) ( Figure  333 6F-G) and alleviated tumor burden (CD11b + ) ( Figure S17 ) in E-Mac-treated leukemia-bearing 334 mice. Collectively, these results demonstrate that MSC-reprogrammed macrophages largely 335 recapitulate the therapeutic effects of MSCs. 336
MSCs reprogram macrophages and reduce leukemia burden through IL-6 337
Residual MSCs in leukemia-bearing mice lost the ability to secrete IL-6 ( Figure 1G-H) . IL-6 is 338 critical for maintaining the stemness and function of MSCs 60 . The recovered host MSCs after 339 donor MSC-treatment expressed comparable Il6 mRNA as healthy MSCs (Figure 4E-G) . 340
Consistently, BM plasma IL-6 levels in MSC-treated leukemia-bearing mice were significantly 341 elevated (> 3 folds) and were comparable to those in healthy mice (p < 0.001) ( Figure 7A ). To 342 investigate the biological consequence of reduced IL-6 on MSCs, we analyzed the MSCs in Il6 -/-343 mice by in vitro proliferation assay. We observed that the Il6 -/-MSCs proliferated at a significantly 344 slower speed than their WT counterparts in vitro (p < 0.001) ( Figure. S18A) . To investigate the 345 role of IL-6 in MSC-mediated therapeutic effects, we directly injected IL-6 proteins (40 µg/kg) 346 into leukemia-bearing mice. However, systemic IL-6 transfusion failed to suppress leukemia 347 ( Figure S18B )，which indicates that MSC-educated leukemic macrophages are distinct from the 348 conventional IL-6-dependent myeloid-derived immune-suppressor cells 61 . We speculated that IL-349 6 might function as an autocrine factor for MSCs to reprogram macrophages in leukemia-bearing 350 mice. In vitro co-culture assay showed that Il6 -/-MSCs compromised their ability to induce Arg1 351 17 expression in macrophages derived from leukemia-bearing mice ( Figure 7B ). In addition, intra-352 BM injection of Il6 -/-MSCs neither improved thrombopoiesis nor reduced tumor burden in 353 leukemia-bearing mice ( Figure 7C-E) . Furthermore, loss of Il6 significantly compromised MSCs' 354 ability to reprogram leukemic macrophages, demonstrated by mild increase of the ratios of Arg1 high 355 macrophage subpopulation in Il6 -/-MSC-treated leukemic mice in vivo (Figure 7F-H Technology Planning Project of Guangdong Province (2017B030314056, 2017B020230004), the 411 grants from the National Natural Science Foundation of China (Grant No 31471117, 31271457, 412 81470281, 81421002, 81730006, 31600948, and 81861148029) were isolated from the compact bone and BMNC of three to four-week-old healthy GFP mice. The 624 isolated MSCs were expanded in vitro, and the secondary passage products were used for 625 transfusion. Leukemia-bearing mice with severe tumor burden (CD11b + % in PB > 60%) were 626 treated by intra-bone-marrow transfusion of donor MSCs. WT mice were treated by the same 627 procedure as treatment control, and leukemia-bearing mice without MSC treatment were used as 628 untreated controls. A sequential doses of MSCs (2.5 × 10^7 MSCs/kg per dose in 20 µL DPBS) 629
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